Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Mark Löwenberg et al.|Journal of Crohn s and Colitis|2019Cited by 183
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, Marieke Pierik, C. Janneke van der Woude et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129